Louisiana State Employees Retirement System Purchases New Stake in Gilead Sciences, Inc. $GILD

Louisiana State Employees Retirement System purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 144,800 shares of the biopharmaceutical company’s stock, valued at approximately $20,181,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in GILD. Strategic Investment Solutions Inc. IL purchased a new stake in shares of Gilead Sciences during the fourth quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its holdings in shares of Gilead Sciences by 71.4% during the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences in the 4th quarter worth approximately $26,000. Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. Finally, Ares Financial Consulting LLC bought a new position in shares of Gilead Sciences during the 4th quarter valued at about $28,000. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Down 1.1%

NASDAQ GILD opened at $123.84 on Friday. The firm has a market capitalization of $153.76 billion, a price-to-earnings ratio of 16.87 and a beta of 0.31. Gilead Sciences, Inc. has a 52 week low of $105.79 and a 52 week high of $157.29. The company has a fifty day moving average of $130.42 and a two-hundred day moving average of $134.33. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.12. The company had revenue of $6.96 billion for the quarter, compared to analysts’ expectations of $6.91 billion. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, analysts predict that Gilead Sciences, Inc. will post -0.8 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: The U.S. FDA approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer, expanding the drug’s addressable market and strengthening Gilead’s oncology growth story. U.S. FDA Approves Trodelvy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
• Positive Sentiment: Merck also received FDA approval for KEYTRUDA combinations that include Trodelvy, which could increase Trodelvy’s use in combination regimens and support broader adoption. FDA Approves KEYTRUDA combinations with Trodelvy
• Positive Sentiment: Gilead also received European Commission approval to expand Trodelvy’s label in metastatic TNBC, further widening the drug’s commercial opportunity outside the U.S. Gilead Wins EC Approval to Expand Trodelvy’s Label in Metastatic TNBC
• Neutral Sentiment: Short-interest data showed no meaningful change, so it does not appear to be a major driver of the stock’s move.
• Negative Sentiment: Despite the Trodelvy approvals, Gilead’s shares still dipped versus the broader market, suggesting investors may be taking profits or focusing on broader market weakness rather than the regulatory upside. Gilead Sciences Dips More Than Broader Market: What You Should Know

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, June 15th. The shares were sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares of the company’s stock, valued at approximately $21,524,408.40. The trade was a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $123.92, for a total value of $371,760.00. Following the transaction, the insider owned 124,234 shares in the company, valued at approximately $15,395,077.28. This trade represents a 2.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $8,930,150 over the last three months. Corporate insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GILD shares. Jefferies Financial Group initiated coverage on shares of Gilead Sciences in a research report on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. The Goldman Sachs Group lifted their price target on shares of Gilead Sciences from $125.00 to $130.00 and gave the company a “neutral” rating in a report on Friday, April 17th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Truist Financial reissued a “buy” rating and set a $157.00 price target (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. Finally, Maxim Group upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 target price on the stock in a research note on Wednesday, May 20th. Twenty-five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $158.41.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.